The peptide drug pipeline in 2026
Last updated: October 27, 2026 · 11 min read · By the Grey Peptides Editorial Board
- Our encyclopedia records ten US approvals of peptides and close relatives so far in 2026, including two peptide tablets: icotrokinra for psoriasis and enlicitide for cholesterol.
- The pipeline behind them is large and lopsided: 331 INN-named peptides have reached phase 2 or later, but only 97 have a trial running now, and obesity drugs dominate the late stage.
- The next big decisions are CagriSema, with an FDA decision anticipated by late 2026, and retatrutide, which Lilly plans to submit for US approval in early 2027. Neither is approved; Lilly states retatrutide cannot be legally sold or marketed for human use.
This year's approvals
Our encyclopedia records ten US approvals so far this year of peptides and their close relatives 1:
| 2026 date | Drug | Molecule | Approved for |
|---|---|---|---|
| February 27 | Navepegritide (Yuviwel) | Peptide conjugate | achondroplasia (accelerated approval) |
| March 17 | Icotrokinra (Icotyde) | Peptide | plaque psoriasis, as a daily tablet |
| March 26 | Insulin icodec (Awiqli) | Protein | type 2 diabetes, once weekly |
| April 1 | Orforglipron (Foundayo) | Small molecule | chronic weight management, as a daily pill |
| May 22 | Bulevirtide (Hepcludex) | Peptide | chronic hepatitis D |
| July 15 | Enlicitide (Lipfendra) | Peptide | high LDL cholesterol, as a daily tablet |
| August 19 | Garetosmab (Pasatru) | Antibody | fibrodysplasia ossificans progressiva |
| August 28 | Rusfertide (Mimrylo) | Peptide | erythrocytosis in polycythaemia vera |
| September 11 | Apitegromab (Isembyld) | Antibody | spinal muscular atrophy, alongside SMN2 therapy |
| September 23 | Insulin efsitora alfa (Onswik) | Protein | type 2 diabetes, once weekly |
Three things stand out. First, two of the peptides are tablets: icotrokinra, approved for moderate-to-severe plaque psoriasis in adults and adolescents, and enlicitide, approved to lower LDL cholesterol 1. Second, the list is not only peptides: orforglipron, Lilly's weight-loss pill, is a small molecule that acts on the same receptor as the GLP-1 peptides, and two of the approvals are antibodies 1. Our guide to what makes a peptide a peptide explains the difference. Third, several approvals are for rare diseases, such as achondroplasia, fibrodysplasia ossificans progressiva and spinal muscular atrophy 1.
The oral peptide turn
Two of this year's peptide approvals are tablets. Oral semaglutide came earlier, paired with an absorption enhancer, SNAC; its label estimates that only about 0.4% to 2% of a dose reaches the blood and requires it to be taken on an empty stomach with no more than 4 ounces of water, 30 minutes before food 2.
Icotrokinra is a 13-amino-acid peptide with a disulfide-bridged ring and non-natural residues that blocks the interleukin-23 receptor; enlicitide is a macrocyclic (ring-shaped) peptide that blocks PCSK9 1. Both were approved for common chronic diseases, psoriasis and high cholesterol 1. Orforglipron, approved the same spring, shows a different strategy: a small molecule that acts on the GLP-1 receptor 1.
How big is the pipeline?
Counting a pipeline depends on what you count. We use the international nonproprietary names (INNs) that the World Health Organization assigns to drugs, which follow naming stems: peptides usually end in '-tide', gonadotropin-releasing hormone drugs in '-relin' or '-relix', vasopressin analogues in '-pressin'. Our pipeline tracker takes every INN-named peptide in the ChEMBL database whose highest recorded phase is 2 or more, then checks ClinicalTrials.gov for what is running now 3.
As of October 1, 2026, that gives 331 molecules: 205 whose furthest point is phase 2, 48 that have reached phase 3 and 78 that have been approved somewhere 3. 267 carry the '-tide' stem. But only 97 have at least one active registered study, 1225 studies in all, and for most of the rest the trail has gone cold 3. Among the molecules with active studies, the most advanced running trial is phase 3 for 33, phase 4 for 28, phase 2 for 25 and phase 1 or earlier for 4 3.
Our broader peptide registry, which also includes natural peptides and compounds without INNs, holds 935 rows: 144 approved, 45 at phase 3, 192 at phase 2 and 12 at phase 1, with the rest endogenous peptides or compounds whose development status is unknown 4.
What the active pipeline is aiming at
ChEMBL records a mechanism for most molecules. Among the 97 peptides with an active study, the mechanisms recorded most often are below; 55 have no mechanism recorded 3.
| Mechanism recorded in ChEMBL | Molecules with active studies |
|---|---|
| Glucagon-like peptide 1 receptor agonist | 9 |
| Parathyroid hormone receptor agonist | 4 |
| Oxytocin receptor agonist | 2 |
| Heat-stable enterotoxin receptor agonist | 2 |
| C-X-C chemokine receptor type 4 antagonist | 2 |
| Melanocortin receptor 4 agonist | 2 |
| Gastric inhibitory polypeptide receptor agonist | 2 |
| Vasopressin receptor agonist | 2 |
| Glucagon receptor agonist | 2 |
The table shows which mechanisms ChEMBL records most often among the peptides with active studies 3.
The obesity race
Most of the money and attention in late-stage peptide development is in obesity and diabetes. The table lists the leading candidates in our encyclopedia, with the number of phase 3 studies registered for each on ClinicalTrials.gov 5 1:
| Compound | How it works | Registered phase 3 studies | Where it stands |
|---|---|---|---|
| Retatrutide | GIP, GLP-1 and glucagon receptor agonist | 14 | Five positive phase 3 trials; Lilly plans a US filing in Q1 2027 |
| CagriSema | Semaglutide plus the amylin analogue cagrilintide | 19 | Filed with FDA December 2025; decision anticipated by late 2026 |
| Maridebart cafraglutide | GLP-1 agonist peptides on a GIP-blocking antibody | 12 | Phase 3 MARITIME programme |
| Survodutide | GLP-1 and glucagon receptor agonist | 12 | Phase 3 in obesity and liver disease |
| Eloralintide | Amylin receptor agonist | 7 | Five phase 3 ENLIGHTEN trials registered from December 2025 |
| Mazdutide | GLP-1 and glucagon receptor agonist | 11 | Approved in China June 27, 2025; not in the US |
| Ecnoglutide | GLP-1 receptor agonist | 7 | Approved in China in 2026; not in the US |
| Amycretin | GLP-1 and amylin receptor agonist | 0 | Phase 1 and 2 published; no registered phase 3 counted |
| Petrelintide | Amylin receptor agonist | 3 | Phase 2 ZUPREME 1 published |
Retatrutide is the most advanced of the next generation. It activates three receptors, GIP, GLP-1 and glucagon, and Lilly reported in July 2026 that it had five positive phase 3 studies; in TRIUMPH-2, adults with obesity or overweight and type 2 diabetes on the highest dose lost up to an average of 20.8% of body weight at 80 weeks. Lilly says it plans to submit retatrutide for US approval in the first quarter of 2027 6. Until then it is investigational: Lilly's own release states that retatrutide cannot be legally sold or marketed for human use 6.
CagriSema, Novo Nordisk's weekly combination of semaglutide and the amylin analogue cagrilintide, is the nearest decision. Novo submitted it to FDA in December 2025, on the REDEFINE 1 and 2 trials, and anticipates a decision by late 2026 7. In February 2026 Novo reported that REDEFINE 4 did not show non-inferiority to tirzepatide: 23.0% against 25.5% weight loss at 84 weeks in the efficacy estimand 7 8.
Behind them come Amgen's maridebart-cafraglutide, which hangs two GLP-1 peptides on an antibody that blocks the GIP receptor; Boehringer Ingelheim and Zealand's survodutide; and a wave of amylin drugs, eloralintide, petrelintide and the dual amylin and GLP-1 agonist amycretin 1. China has moved faster on two: mazdutide was approved there in June 2025 and ecnoglutide in 2026, neither with a US application 1.
Beyond weight loss
The rest of the pipeline is more varied than the headlines suggest. This year's approvals include rusfertide, a hepcidin mimetic that controls red cell production in polycythaemia vera; bulevirtide, which blocks the receptor hepatitis D uses to enter liver cells; and navepegritide, a long-acting form of the growth peptide CNP for children with achondroplasia 1. Radioligands, peptides or peptide-like molecules that carry radioactive atoms to tumours, keep expanding: Pluvicto's current label (effective August 12, 2026) covers earlier-stage disease as well as the original indication, and our entry on vipivotide tetraxetan sets out the trials behind it 1.
Gut peptides are another cluster. Glepaglutide met its primary endpoint in short bowel syndrome, and apraglutide is in development for the same condition 1. Not every story ends well: larazotide, once the leading drug candidate for coeliac disease, had its phase 3 trial terminated by its sponsor 1. Liver disease is a growing target, with pemvidutide given Breakthrough Therapy designation for MASH in January 2026 and survodutide in phase 3 for the same condition 1.
Readouts due this quarter
Each molecule in our pipeline tracker carries the expected primary completion date of its next registered study. Between October and December 2026, 36 molecule-study pairs have a readout due; the phase 2 and 3 studies among them are below 3. A primary completion date is the sponsor's estimate of when the last participant is measured, not a promise that results will be published then, and 5 registered readouts in the tracker are already overdue without an update 3.
| Expected | Peptide | Phase | Study |
|---|---|---|---|
| 2026-10 | oxytocin | Phase 2 | NCT06036004: Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus |
| 2026-10 | retatrutide | Phase 3 | NCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moder |
| 2026-10-01 | dulaglutide | Phase 3 | NCT06257966: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination |
| 2026-10-15 | semaglutide | Phase 2 | NCT07505303: MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial |
| 2026-10-15 | vipivotide tetraxetan | Phase 2 | NCT06894511: An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With |
| 2026-10-29 | pasireotide | Phase 2 | NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia |
| 2026-10-31 | setmelanotide | Phase 2 | NCT06772597: A Study of Setmelanotide in Patients With Prader-Willi Syndrome |
| 2026-11 | degarelix | Phase 2 | NCT03951831: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Ca |
| 2026-11 | goserelin | Phase 2 | NCT05607004: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer |
| 2026-11 | lanreotide | Phase 3 | NCT05050942: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GE |
| 2026-11 | bulevirtide | Phase 2 | NCT07142811: A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection |
| 2026-11-02 | gallium oxodotreotide | Phase 2 | NCT05691465: Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatat |
| 2026-11-11 | triptorelin | Phase 3 | NCT05050084: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less I |
| 2026-11-13 | olatorepatide | Phase 2 | NCT07431086: Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US |
| 2026-11-30 | ecnoglutide | Phase 2 | NCT07553299: A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participant |
| 2026-12-30 | gozetotide | Phase 2 | NCT06145633: Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistan |
| 2026-12-31 | anamorelin | Phase 3 | NCT03637816: Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lun |
Who leads
The obesity race has made two companies dominant. Eli Lilly has tirzepatide on the market, orforglipron newly approved, retatrutide heading for filing and eloralintide in phase 3; Novo Nordisk has semaglutide, CagriSema under review, amycretin in development and insulin icodec newly approved 1 6 7. Amgen, Boehringer Ingelheim with Zealand Pharma, and Roche with Zealand are the main challengers, and Chinese developers such as Innovent and Sciwind have reached approval at home first 1.
Outside obesity, smaller companies built several of this year's approvals. Icotrokinra came out of a collaboration between Johnson & Johnson and Protagonist Therapeutics, a University of Queensland spin-out 9; rusfertide, developed as PTG-300, is now marketed by Takeda 1. Ascendis built navepegritide, known in development as TransCon CNP, as a once-weekly alternative to a daily drug, and Merck's enlicitide is a macrocyclic peptide designed to be swallowed, in the PCSK9-inhibitor class 1.
What to watch next
Four events will shape the next twelve months. The FDA decision on CagriSema, anticipated by late 2026, will test whether an amylin and GLP-1 combination can win approval after trailing tirzepatide head to head 7. Lilly's planned retatrutide submission in early 2027 would bring a GIP, GLP-1 and glucagon triple agonist to review 6. Phase 3 results from the amylin drugs will show whether amylin can stand on its own as a weight-loss target. And real-world uptake of the new oral peptides will show whether patients and payers prefer a daily tablet to a weekly or monthly injection.
How to read pipeline news
Three cautions help. Databases lag. ChEMBL, which our tracker and registry draw on, records the highest phase a molecule has reached, and it can take months to catch up with an approval. As we write, it still lists 3 of this year's approvals (rusfertide, enlicitide, navepegritide) as not yet approved; our encyclopedia entries, which are checked against Drugs@FDA, are the more current source 4 1.
Phases are not probabilities. A compound in phase 3 has passed earlier tests, but phase 3 can still fail, as larazotide's and taspoglutide's did 1. Our article on elamipretide's approval shows how narrow an approval can be.
In the pipeline does not mean available. FDA says it has warned companies that illegally sold unapproved drugs containing retatrutide, among other GLP-1 drugs, falsely labelled 'for research purposes' or 'not for human consumption' 10. Those products are not approved, and Lilly states that retatrutide cannot be legally sold or marketed for human use 6. Our guide to spotting a fake certificate of analysis explains why a seller's paperwork does not close that gap.
Frequently asked questions
What new peptide drugs were approved in 2026?
Our encyclopedia records ten US approvals of peptides and close relatives so far in 2026, including icotrokinra (Icotyde) and enlicitide (Lipfendra), both tablets, plus navepegritide, bulevirtide, rusfertide and two once-weekly insulins.
When will retatrutide be approved?
It is not approved. Lilly said in July 2026 that it plans to submit retatrutide for US approval in the first quarter of 2027; a decision would follow the review.
When is the FDA decision on CagriSema?
Novo Nordisk submitted CagriSema to FDA in December 2025 and anticipates a decision by late 2026. As of October 27, 2026 it is not approved.
How many peptides are in clinical trials?
As of October 1, 2026, 331 INN-named peptides had reached phase 2 or later in ChEMBL, and 97 had at least one active study on ClinicalTrials.gov.
Related on Grey Peptides
Sources
- Grey Peptides encyclopedia: approval details for each entry, checked against Drugs@FDA, EMA and company announcements with the read dates shown on each entry; rusfertide's approval date from Drugs@FDA (NDA 220605), read October 3, 2026.
- Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets US prescribing information, sections 2.1 and 12.3. DailyMed version 14, effective January 30, 2026; read October 27, 2026. DailyMed
- Grey Peptides pipeline tracker data (assets/pipeline-data.json): 331 INN-named peptides at ChEMBL phase 2 or later with live ClinicalTrials.gov status, read October 1, 2026.
- Grey Peptides peptide registry (assets/registry.json), 935 rows from ChEMBL, openFDA, UniProt, PubMed, PubChem and ClinicalTrials.gov, generated 2026-10-02.
- Grey Peptides evidence counts (_ops/evidence_counts.json): ClinicalTrials.gov studies by phase for each entry, read October 3, 2026.
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. News release, July 23, 2026. Read October 3 and October 27, 2026.
- Novo Nordisk (the manufacturer). Form 6-K, February 23, 2026 (SEC EDGAR): REDEFINE 4 (CagriSema 23.0% vs tirzepatide 25.5% at 84 weeks, efficacy estimand; non-inferiority not achieved); CagriSema submitted to FDA in December 2025 on REDEFINE 1 and 2; decision anticipated by late 2026. Read October 27, 2026; cited without a link.
- Clinical Trials Arena. Novo Nordisk's CagriSema bested by Lilly's Zepbound in head-to-head trial. February 23, 2026 (trade press; filing December 2025 on REDEFINE 1 and 2, decision anticipated late 2026). Read October 3, 2026.
- Institute for Molecular Bioscience, University of Queensland. 'Life-changing' psoriasis pill gets FDA approval. April 24, 2026 (icotrokinra developed under a collaboration between Johnson & Johnson and UQ spin-out Protagonist Therapeutics). Read October 3 and October 27, 2026.
- US FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026; read October 27, 2026). FDA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead